[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts

Authors :: Erichsen, Kamille Dumong
Johnbeck, Camilla Bardram
Björkling, Fredrik
Madsen, Jacob
Bzorek, Michael
Jensen, Peter Buhl
Højgaard, Liselotte
Sehested, Maxwell
Kjær, Andreas
Jensen, Mette Munk
Erichsen, Kamille Dumong
Johnbeck, Camilla Bardram
Björkling, Fredrik
Madsen, Jacob
Bzorek, Michael
Jensen, Peter Buhl
Højgaard, Liselotte
Sehested, Maxwell
Kjær, Andreas
Jensen, Mette Munk
Source :: Erichsen , K D , Johnbeck , C B , Björkling , F , Madsen , J , Bzorek , M , Jensen , P B , Højgaard , L , Sehested , M , Kjær , A & Jensen , M M 2013 , ' [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts ' , P L o S One , vol. 8 , no. 1 , e53410 , pp. 1-8 .
Publication Year :: 2013
Abstract: APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake.

Database :: OAIster
Journal :: Erichsen , K D , Johnbeck , C B , Björkling , F , Madsen , J , Bzorek , M , Jensen , P B , Højgaard , L , Sehested , M , Kjær , A & Jensen , M M 2013 , ' [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts ' , P L o S One , vol. 8 , no. 1 , e53410 , pp. 1-8 .
Notes :: English
Publication Type :: Electronic Resource
Accession number :: edsoai.ocn889787474
Document Type :: Electronic Resource

Tools